InvestorsHub Logo
Followers 20
Posts 2619
Boards Moderated 0
Alias Born 01/27/2022

Re: Triple88 post# 424095

Thursday, 05/09/2024 10:08:34 AM

Thursday, May 09, 2024 10:08:34 AM

Post# of 426504
Honestly, I don't think one has anything do with the other. The sales/distribution methods in Europe are much different than Canada and the US.

I agree, Vascepa has been a bit of a disappointment in Canada. $17-18M in full-year revenue after this many years is pretty disappointing. I wasn't able to listen to the earnings call today, but am hoping to listen to the replay when available.

I think a lot of this goes back to the GIA strategy. HLS is not a big company. They are tiny, and they are boot-strapping it (hence, why they brought in Pfizer originally).

Vascepa in the hands of a BP probably would have gone much differently.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News